Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced NSCLC Read more
Contact Us
Ryan Dackor, Ph.D.
Director, Clinical Operations
919.270.9404
info@gridthr.com
For Investors, Partnering and Media Information, please fill out and submit the information below: